NOVAVAX AND SANOFI ANNOUNCE CO-EXCLUSIVE LICENSING AGREEMENT TO CO-COMMERCIALIZE COVID-19 VACCINE AND DEVELOP NOVEL COVID-19-INFLUENZA COMBINATION VACCINES

MLA

“Novavax and Sanofi Announce Co-Exclusive Licensing Agreement to Co-Commercialize Covid-19 Vaccine and Develop Novel Covid-19-Influenza Combination Vaccines.” States News Service, 10 May 2024. EBSCOhost, widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsggo&AN=edsgcl.793626912&authtype=sso&custid=ns315887.

APA

Novavax and Sanofi Announce Co-Exclusive Licensing Agreement to Co-Commercialize Covid-19 Vaccine and Develop Novel Covid-19-Influenza Combination Vaccines. (2024, May 10). States News Service.

Chicago

States News Service. 2024. “Novavax and Sanofi Announce Co-Exclusive Licensing Agreement to Co-Commercialize Covid-19 Vaccine and Develop Novel Covid-19-Influenza Combination Vaccines,” May 10. http://widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsggo&AN=edsgcl.793626912&authtype=sso&custid=ns315887.